Life Sciences

Watson for Drug Discovery Identifies Proteins Associated with Cardiovascular Disease

Share this post:

Capsule close-up.

Heart attack and stroke are 2 of the top 10 causes of death worldwide. Identifying the proteins involved in each of them is the beginning of a journey to understanding how these diseases develop. In a novel experiment presented at the American Heart Association Scientific Sessions on November 12, 2017, and published in a supplement of the journal Ciruculation, cardiology researchers tested Watson’s ability to rank proteins they knew were associated with cardiovascular disease. In the experiment, researchers gave Watson a list of 1,274 proteins associated with many diseases, some of which the researchers knew were associated with atherosclerosis and heart failure to see if Watson could identify them.

Watson used a training sample of proteins known to be associated with atherosclerosis and heart failure to rank the remaining proteins, by comparing literature fingerprints. Watson ranked the cardiovascular proteins significantly higher than non-cardiovascular proteins and its predictive ability improved with increased specificity of training on the cardiovascular disease phenotypes of coronary atherosclerosis and heart failure. These data demonstrate that Watson for Drug Discovery does have the ability to help researchers by classifying proteins associated with cardiovascular disease and that the predictive ability is honed with increasing specificity of disease phenotype.1

The next step will include analyzing blood samples taken from about 20,000 patients to evaluate whether Watson can successfully identify new proteins for researchers that have not previously been associated with heart failure and atherosclerosis. Congratulations to Scott Spangler and Alix Lacoste for their work in demonstrating Watson’s capabilities in cardiovascular disease discovery.

1. Christian T Ruff, Alix Lacoste, Francesco Nordio, Christina L Fanola, Michael G Silverman, Elenee Argentinis, Scott Spangler, Marc S Sabatine. Classification of Cardiovascular Proteins Involved in Coronary Atherosclerosis and Heart Failure Using Watson’s Cognitive Computing Technology. Circulation. 2017;136:A16678

 

 

More Life Sciences stories

The State of Telehealth, and its Role in the Fight Against Opioid Use Disorder

Written by Mustafa Karakus | Blog Post, Cognitive Computing, Government...

Telehealth is ready to take center stage. Telehealth is in the fight against opioid use disorder. But are consumers and healthcare providers ready to start giving and receiving care via their computers and smartphones, and are private health plans ready to pay for it? Based on recent media reports tracking sentiment toward the technology, telehealth is definitely on an upward trend ...read more


Testing Blockchain Technology for Clinical Trials in Canada

Written by Uli Brödl | Blog Post, Healthcare Data Analytics

By: Dr. Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. The healthcare industry is undergoing significant changes due to the vast amounts of disparate data being generated. There is a huge need for transformative healthcare solutions where healthcare researchers, providers, and patients have access to a 360-degree view of health data. ...read more


Examining the variation in cancer care

Written by Watson Health | AI, Blog Post, Oncology & Genomics

As medicine moves forward—making advances in prevention, detection, care delivery and more—cancer marches on, killing nearly 2 million Europeans every year. As one would expect, the reasons are as complex as cancer itself and one of the most significant reasons is variability in care. Here, we explore some of the reasons behind the variation and how AI may be able to help. ...read more